It is known that the sensitivity to TKIs is strictly correlated with the various types of KIT/PDGFRA mutations, with the longest progression-free and overall survival associated to patients whose GIST harbors exon 11 mutations [4,5,6,7,8,9]. Here, PDGFRA is linked to gastrointestinal stromal tumor.